Advanced

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders

Hall, Sara LU ; Janelidze, Shorena LU ; Zetterberg, Henrik LU ; Brix, Britta ; Mattsson, Niklas LU ; Surova, Yulia LU ; Blennow, Kaj LU and Hansson, Oskar LU (2019) In Movement Disorders
Abstract

Background: CSF concentration of neurogranin has been suggested as a biomarker for synapse dysfunction. Objectives: To investigate CSF neurogranin in parkinsonian disorders compared to controls and Alzheimer's disease and the possible correlations between neurogranin and cognitive and motor impairment. Methods: We included 157 patients with PD, 29 with PD with dementia, 11 with dementia with Lewy bodies, 26 with MSA, 21 with PSP, 6 with corticobasal syndrome, 47 controls, and 124 with Alzheimer's disease. CSF neurogranin was measured using two enzyme-linked immunosorbent assays; from EUROIMMUN and the University of Gothenburg. Results: We found a strong correlation between CSF neurogranin-EI and CSF neurogranin–University of Gothenburg... (More)

Background: CSF concentration of neurogranin has been suggested as a biomarker for synapse dysfunction. Objectives: To investigate CSF neurogranin in parkinsonian disorders compared to controls and Alzheimer's disease and the possible correlations between neurogranin and cognitive and motor impairment. Methods: We included 157 patients with PD, 29 with PD with dementia, 11 with dementia with Lewy bodies, 26 with MSA, 21 with PSP, 6 with corticobasal syndrome, 47 controls, and 124 with Alzheimer's disease. CSF neurogranin was measured using two enzyme-linked immunosorbent assays; from EUROIMMUN and the University of Gothenburg. Results: We found a strong correlation between CSF neurogranin-EI and CSF neurogranin–University of Gothenburg (Rs = 0.890; P < 0.001). Neurogranin was decreased in PD, PD with dementia, MSA, and PSP compared to controls and Alzheimer's disease. Neurogranin did not correlate with motor or cognitive impairment, longitudinal decline, or progression to dementia in PD. Conclusions: CSF neurogranin is decreased in parkinsonian disorders compared to controls, emphasizing the importance of synaptic dysfunction in these disorders.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
cerebrospinal fluid, neurogranin, parkinsonian disorders
in
Movement Disorders
publisher
John Wiley & Sons
external identifiers
  • scopus:85076775640
  • pmid:31837067
ISSN
0885-3185
DOI
10.1002/mds.27950
language
English
LU publication?
yes
id
fd4dc967-532b-45dd-a831-740875e53399
date added to LUP
2020-01-14 09:27:06
date last changed
2020-01-16 04:09:25
@article{fd4dc967-532b-45dd-a831-740875e53399,
  abstract     = {<p>Background: CSF concentration of neurogranin has been suggested as a biomarker for synapse dysfunction. Objectives: To investigate CSF neurogranin in parkinsonian disorders compared to controls and Alzheimer's disease and the possible correlations between neurogranin and cognitive and motor impairment. Methods: We included 157 patients with PD, 29 with PD with dementia, 11 with dementia with Lewy bodies, 26 with MSA, 21 with PSP, 6 with corticobasal syndrome, 47 controls, and 124 with Alzheimer's disease. CSF neurogranin was measured using two enzyme-linked immunosorbent assays; from EUROIMMUN and the University of Gothenburg. Results: We found a strong correlation between CSF neurogranin-EI and CSF neurogranin–University of Gothenburg (R<sub>s</sub> = 0.890; P &lt; 0.001). Neurogranin was decreased in PD, PD with dementia, MSA, and PSP compared to controls and Alzheimer's disease. Neurogranin did not correlate with motor or cognitive impairment, longitudinal decline, or progression to dementia in PD. Conclusions: CSF neurogranin is decreased in parkinsonian disorders compared to controls, emphasizing the importance of synaptic dysfunction in these disorders.</p>},
  author       = {Hall, Sara and Janelidze, Shorena and Zetterberg, Henrik and Brix, Britta and Mattsson, Niklas and Surova, Yulia and Blennow, Kaj and Hansson, Oskar},
  issn         = {0885-3185},
  language     = {eng},
  month        = {12},
  publisher    = {John Wiley & Sons},
  series       = {Movement Disorders},
  title        = {Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders},
  url          = {http://dx.doi.org/10.1002/mds.27950},
  doi          = {10.1002/mds.27950},
  year         = {2019},
}